English 
     
   首 页
   热点信息
学生工作办公室简介
联系我们
语言中心主任致辞
培养方案
专业介绍
招生问答
请加QQ群312279505
刘庄教授课题组在Biomaterials上发表论文
发布时间:2017-10-18 点击:1142

题目:

Tumor Vasculature Normalization by Orally Fed Erlotinib to Modulate the Tumor Microenvironment for Enhanced Cancer Nanomedicine and Immunotherapy


作者:

Qian Chena, Ligeng Xua, Jiawen Chena, Zhijuan Yanga, Chao Lianga, Yu Yangb, Zhuang Liua*


单位:

aInstitute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-based Functional Materials and Devices, Soochow University, Suzhou, Jiangsu 215123, China

bState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Avenida da Universidad, Taipa, Macau, China


摘要:

The abnormal tumor vasculature is one of key reasons that lead to the limited tumor perfusion as well as hypoxic and immunosuppressive tumor microenvironment (TME). Herein, we uncover that by normalizingthe tumor vasculature with erlotinib, a specific inhibitor of epidermal growth factor receptor(EGFR), the tumor perfusion and tumor oxygenation statuses in different types of tumors including murine breast tumors, colorectal tumors, and squamous cell carcinoma tumors, could be remarkably enhanced. As the results, the tumor uptake of drug-loaded nanoparticles as well as their interstitial penetration within the tumor would be greatly increased for mice pre-treated with erlotinib at the oral feeding dose of 50 mg/kg, leading to remarkably improved chemotherapeutic efficacy of nanomedicine. On the other hand, owing to the erlotinib-induced normalization of tumor vasculatures, the relieved hypoxic state in the three different types of tumors could alter the immunosuppressive TME into immunosupportive. Such an effect together with the increased tumor retention of anti-PDL1 antibody, a clinically approved checkpoint blockade agent, finally contributes to the greatly improved tumor inhibition effect in cancer immunotherapy. Therefore, our work presents a general yet effective strategy using a clinical drug to enhance the efficacies of cancer nanomedicine and immunotherapy by normalizing tumor vasculatures and modulating TME.


影响因子:

8.402


分区情况:

一区


链接:

http://www.sciencedirect.com/science/article/pii/S0142961217306051



责任编辑:向丹婷


Copyright © 2012 苏州大学纳米科学技术学院 All Rights Reserved.
  地址:苏州工业园区仁爱路199号910楼  邮编:215123
您是第 位访问者